140.54
91.31 (00.65%)
As of Feb 09, 2023
BioNTech SE [BNTX]
As of Mar 20, 2024 | Source: Annual Report to the SEC
Company Overview
Biontech Se, is a global next-generation immunotherapy company pioneering novel medicines against cancer, infectious diseases and other serious diseases.
| Country | United States |
| Phone Number | 0049613190840 |
| Industry | Chemicals And Allied Products |
| Employees | 6,133 |
| CEO | Prof. Ugur Sahin |
| Website | www.biontech.com |
Recent Stories
Financial Overview
| Revenue | 3,819 M |
| Operating Revenue | 690 M |
| Profits | 930 M |
| Net Cash | -2,362 M |
Management Effectiveness
| Return on Equity | -1.26% |
| Return on Assets | -1.11% |
| Turnover Ratio | 0.17 M |
| EBIT | 690 M |
Profit Ratios
| Gross Margin | 4,419 M |
| Operating Margin | 18.08% |
| Profit as % of Revenues | 474.99% |
| Profit as % of Assets | 4.02% |
| Profit as % of Stockholder Equity | 4.6% |
Balance Sheet and Cash Flow Measures
| Total Assets | 23,006 M |
| Total Liabilities | 2,760 M |
| Operating Cash Flow | 5,371 M |
| Investing Cash Flow | -6,954 M |
| Financing Cash Flow | -779 M |